Articles Comments

Health and Diseases » Smoking Cessation » New warning label for smoking cessation medication of varenicline (Cantix, Pfizer) from FDA

New warning label for smoking cessation medication of varenicline (Cantix, Pfizer) from FDA

New warning label for safety and efficacy of smoking-cessation medication of varenicline marketed as Cantix from Pfizer company just announced by the U.S. Food and Drug Administration (FDA).

The announcement states that varenicline is effective in stopping the smoking habit in patients with cardiovascular disease, but also linked to small increased risk of cardiovascular adverse events.

This new label based on the result of previous studies that showed potential risk of cardiovascular adverse events when taken by patients with cardiovascular disease to quit smoking.
The study also advised the doctors to consider the risks and benefits of the drug before prescribing to their patients.

Current announcement by agency also provide information about the use of varenicline in patients with chronic obstructive pulmonary disease (CPOD).
Although varenicline effective than placebo in helping patients to quit smoking, but this drug also can increase the risk of any adverse events.

In new label also stated that patients should taking varenicline 7 days before their smoking quit date or begin the drug and then quit smoking between day 8 and day 35 of treatment.

Filed under: Smoking Cessation · Tags: , , , , , ,

Leave a Reply

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>